Skip to main content
Top
Published in:

26-06-2023 | Mastectomy | Breast Oncology

Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients

Authors: Elizaveta Vasilyeva, MD, Jeremy Hamm, MSc, Alan Nichol, MD, Kathryn V. Isaac, MD, Amy Bazzarelli, MD, Carl Brown, MD, Caroline Lohrisch, MD, Elaine McKevitt, MD

Published in: Annals of Surgical Oncology | Issue 11/2023

Login to get access

Abstract

Introduction

Randomized trials demonstrated equivalent survival between breast-conserving surgery combined with radiotherapy (BCT) and mastectomy alone. Contemporary retrospective studies using pathological stage have reported improved survival with BCT. However, pathological information is unknown before surgery. To mimic real-world surgical decision-making, this study assesses oncological outcomes by using clinical nodal status.

Methods

Female patients aged 18–69 years who were treated with upfront BCT or mastectomy between 2006 and 2016 for T1-3N0-3 breast cancer were identified by using prospective, provincial database. The patients were divided into clinically node-positive (cN+) and node-negative (cN0) strata. Multivariable logistic regression was used to assess the effect of local treatment type on overall survival (OS), breast cancer-specific survival (BCSS), and locoregional recurrence (LRR).

Results

Of 13,914 patients, 8228 had BCT and 5686 had mastectomy. Mastectomy patients had higher-risk clinicopathological factors: pathologically positive axillary staging was 21% in BCT and 38% in mastectomy groups. Most patients received adjuvant systemic therapy. For cN0 patients, 7743 had BCT and 4794 had mastectomy. On multivariable analysis, BCT was associated with improved OS (hazard ratio [HR] 1.37, p < 0.001) and BCSS (HR 1.32, p < 0.001), whereas LRR was not different between the groups (HR 0.84, p = 0.1). For cN+ patients, 485 had BCT and 892 had mastectomy. On multivariable analysis, BCT was associated with improved OS (HR 1.46, p = 0.002) and BCSS (HR 1.44, p = 0.008), whereas LRR was not different between the groups (HR 0.89, p = 0.7).

Conclusions

In the era of contemporary systemic therapy, BCT was associated with better survival than mastectomy, without an increased risk of locoregional recurrence for both cN0 and cN+ presentations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed
2.
go back to reference Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.CrossRefPubMed Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.CrossRefPubMed
3.
go back to reference Blichert-Toft M, Nielsen M, Düring M, et al. Long-term results of breast conserving surgery vs mastectomy for early-stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47(4):672–81.CrossRefPubMed Blichert-Toft M, Nielsen M, Düring M, et al. Long-term results of breast conserving surgery vs mastectomy for early-stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47(4):672–81.CrossRefPubMed
4.
go back to reference Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early-stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119(7):1402–11.CrossRefPubMed Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early-stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119(7):1402–11.CrossRefPubMed
5.
go back to reference Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149(3):267–74.CrossRefPubMed Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149(3):267–74.CrossRefPubMed
6.
go back to reference Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (≤ 40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast. 2015;24(3):175–81.CrossRefPubMed Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (≤ 40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast. 2015;24(3):175–81.CrossRefPubMed
7.
go back to reference Hofvind S, Holen Å, Aas T, Roman M, Sebuødegård S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015;41(10):1417–22.CrossRefPubMed Hofvind S, Holen Å, Aas T, Roman M, Sebuødegård S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015;41(10):1417–22.CrossRefPubMed
8.
go back to reference van Maaren MC, de Munck L, de Bock GH, et al. 10-year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70.CrossRefPubMed van Maaren MC, de Munck L, de Bock GH, et al. 10-year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70.CrossRefPubMed
9.
go back to reference Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygård JF. Better survival after breast-conserving therapy compared to mastectomy when axillary node status is positive in early-stage breast cancer: a registry-based follow-up study of 6387 Norwegian women participating in screening, primarily operated between 1998 and 2009. World J Surg Oncol. 2017;15(1):118.CrossRefPubMedPubMedCentral Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygård JF. Better survival after breast-conserving therapy compared to mastectomy when axillary node status is positive in early-stage breast cancer: a registry-based follow-up study of 6387 Norwegian women participating in screening, primarily operated between 1998 and 2009. World J Surg Oncol. 2017;15(1):118.CrossRefPubMedPubMedCentral
10.
go back to reference Kim K, Park HJ, Shin KH, Kim JH, Choi DH, Park W, Ahn SD, Kim SS, Kim DY, Kim TH, Kim JH, Kim J. Breast conservation therapy versus mastectomy in patients with T1-2N1 triple-negative breast cancer: pooled analysis of KROG 14-18 and 14-23. Cancer Res Treat. 2018;50(4):1316–23.CrossRefPubMedPubMedCentral Kim K, Park HJ, Shin KH, Kim JH, Choi DH, Park W, Ahn SD, Kim SS, Kim DY, Kim TH, Kim JH, Kim J. Breast conservation therapy versus mastectomy in patients with T1-2N1 triple-negative breast cancer: pooled analysis of KROG 14-18 and 14-23. Cancer Res Treat. 2018;50(4):1316–23.CrossRefPubMedPubMedCentral
11.
go back to reference Wang J, Deng JP, Sun JY, et al. Noninferior outcome after breast-conserving treatment compared to mastectomy in breast cancer patients with four or more positive lymph nodes. Front Oncol. 2019;9:143.CrossRefPubMedPubMedCentral Wang J, Deng JP, Sun JY, et al. Noninferior outcome after breast-conserving treatment compared to mastectomy in breast cancer patients with four or more positive lymph nodes. Front Oncol. 2019;9:143.CrossRefPubMedPubMedCentral
12.
go back to reference Corradini S, Reitz D, Pazos M, Schönecker S, Braun M, Harbeck N, Matuschek C, Bölke E, Ganswindt U, Alongi F, Niyazi M, Belka C. Mastectomy or breast-conserving therapy for early breast cancer in real-life clinical practice: outcome comparison of 7565 cases. Cancers (Basel). 2019;11(2):160.CrossRefPubMedPubMedCentral Corradini S, Reitz D, Pazos M, Schönecker S, Braun M, Harbeck N, Matuschek C, Bölke E, Ganswindt U, Alongi F, Niyazi M, Belka C. Mastectomy or breast-conserving therapy for early breast cancer in real-life clinical practice: outcome comparison of 7565 cases. Cancers (Basel). 2019;11(2):160.CrossRefPubMedPubMedCentral
13.
go back to reference Almahariq MF, Quinn TJ, Siddiqui Z, et al. Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer. Radiother Oncol. 2020;142:186–94.CrossRefPubMed Almahariq MF, Quinn TJ, Siddiqui Z, et al. Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer. Radiother Oncol. 2020;142:186–94.CrossRefPubMed
14.
go back to reference de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48,986 women. JAMA Surg. 2021;156(7):628–37.CrossRefPubMedPubMedCentral de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48,986 women. JAMA Surg. 2021;156(7):628–37.CrossRefPubMedPubMedCentral
15.
go back to reference Wrubel E, Natwick R, Wright GP. Breast-conserving therapy is associated with improved survival compared with mastectomy for early-stage breast cancer: a propensity score matched comparison using the national cancer database. Ann Surg Oncol. 2021;28(2):914–9.CrossRefPubMed Wrubel E, Natwick R, Wright GP. Breast-conserving therapy is associated with improved survival compared with mastectomy for early-stage breast cancer: a propensity score matched comparison using the national cancer database. Ann Surg Oncol. 2021;28(2):914–9.CrossRefPubMed
16.
go back to reference Chu QD, Hsieh MC, Yi Y, Lyons JM, Wu XC. Outcomes of breast-conserving surgery plus radiation vs mastectomy for all subtypes of early-stage breast cancer: analysis of more than 200,000 women. J Am Coll Surg. 2022;234(4):450–64.CrossRefPubMed Chu QD, Hsieh MC, Yi Y, Lyons JM, Wu XC. Outcomes of breast-conserving surgery plus radiation vs mastectomy for all subtypes of early-stage breast cancer: analysis of more than 200,000 women. J Am Coll Surg. 2022;234(4):450–64.CrossRefPubMed
17.
go back to reference Li P, Li L, Xiu B, et al. The prognoses of young women with breast cancer (≤ 35 years) with different surgical options: a propensity score matching retrospective cohort study. Front Oncol. 2022;12:795023.CrossRefPubMedPubMedCentral Li P, Li L, Xiu B, et al. The prognoses of young women with breast cancer (≤ 35 years) with different surgical options: a propensity score matching retrospective cohort study. Front Oncol. 2022;12:795023.CrossRefPubMedPubMedCentral
18.
go back to reference Lanning RM, Morrow M, Riaz N, et al. The effect of adjuvant trastuzumab on locoregional recurrence of human epidermal growth factor receptor 2-positive breast cancer treated with mastectomy. Ann Surg Oncol. 2015;22(8):2517–25.CrossRefPubMed Lanning RM, Morrow M, Riaz N, et al. The effect of adjuvant trastuzumab on locoregional recurrence of human epidermal growth factor receptor 2-positive breast cancer treated with mastectomy. Ann Surg Oncol. 2015;22(8):2517–25.CrossRefPubMed
19.
go back to reference Sheridan W, Scott T, Caroline S, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat. 2014;147(3):617–29.CrossRefPubMed Sheridan W, Scott T, Caroline S, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat. 2014;147(3):617–29.CrossRefPubMed
20.
go back to reference Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20(11):3469–76.CrossRefPubMedPubMedCentral Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20(11):3469–76.CrossRefPubMedPubMedCentral
21.
go back to reference Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.CrossRefPubMed Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.CrossRefPubMed
22.
go back to reference Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial [published correction appears in Lancet Oncol. 2015;16(3):e105]. Lancet Oncol. 2015;16(3):266–73. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial [published correction appears in Lancet Oncol. 2015;16(3):e105]. Lancet Oncol. 2015;16(3):266–73.
23.
go back to reference Nichol AM, Chan EK, Lucas S, et al. The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study. Int J Rad Onc Biol Phys. 2017;98(4):829–39.CrossRef Nichol AM, Chan EK, Lucas S, et al. The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study. Int J Rad Onc Biol Phys. 2017;98(4):829–39.CrossRef
25.
go back to reference van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Soft. 2011;45:1–67.CrossRef van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Soft. 2011;45:1–67.CrossRef
26.
29.
go back to reference Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28(3):289–94.CrossRefPubMed Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28(3):289–94.CrossRefPubMed
31.
go back to reference Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34:2221–31.CrossRefPubMedPubMedCentral Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34:2221–31.CrossRefPubMedPubMedCentral
32.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRef
33.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.CrossRef
34.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.CrossRef
35.
go back to reference Kapur H, Chen L, Warburton R, et al. De-escalating breast cancer surgery: should we apply quality indicators from other jurisdictions in Canada? Curr Oncol. 2021;29(1):144–54.CrossRefPubMedPubMedCentral Kapur H, Chen L, Warburton R, et al. De-escalating breast cancer surgery: should we apply quality indicators from other jurisdictions in Canada? Curr Oncol. 2021;29(1):144–54.CrossRefPubMedPubMedCentral
Metadata
Title
Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients
Authors
Elizaveta Vasilyeva, MD
Jeremy Hamm, MSc
Alan Nichol, MD
Kathryn V. Isaac, MD
Amy Bazzarelli, MD
Carl Brown, MD
Caroline Lohrisch, MD
Elaine McKevitt, MD
Publication date
26-06-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 11/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-13784-x

Other articles of this Issue 11/2023

Annals of Surgical Oncology 11/2023 Go to the issue
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now